Last updated on February 2018

Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin

Brief description of study

A Blind-adjudication Multi-center Phase II Randomized Clinical Trial of Continuous Low-dose Intravenous Heparin Therapy in Coiled Low-grade Aneurysmal Subarachnoid Hemorrhage Patients with Significant Hemorrhage Burden.

Detailed Study Description

The primary objective of this study is to investigate the safety and clinical effect of a continuous low-dose intravenous unfractionated heparin (LDIVH) infusion for the prevention of aneurysmal subarachnoid hemorrhage (aSAH) induced neurocognitive dysfunction and other delayed neurological deficits.

Additionally, increased blood and CSF levels of certain inflammatory biomarkers (IL-6, hsCRP, etc) have been correlated to aSAH patients with poor clinical outcomes. Unfractionated heparin (UFH) has known anti-inflammatory actions. As a result, a secondary objective of this study will be to evaluate whether LDIVH can reduce blood and CSF inflammatory biomarkers levels compared to controls and whether there is any association between inflammatory biomarker levels and cognitive outcomes in aSAH.

Clinical Study Identifier: NCT02501434

Find a site near you

Start Over

University of Louisville

Louisville, KY United States
  Connect »

Yale University

New Haven, CT United States
  Connect »

University of Florida

Gainesville, FL United States
  Connect »

Rush University

Chicago, IL United States
  Connect »

University of Michigan

Ann Arbor, MI United States
  Connect »